Brief: FDA Denies Sun Pharma Advanced Research's Appeal of Complete Response Letter For Taclantis

Sun Pharma Advanced Research

23/02/2021 11:11

Feb 23 (Reuters) - Sun Pharma Advanced Research Co Ltd
 SPRC.NS :
    * FDA HAS DENIED COMPANY'S APPEAL OF COMPLETE RESPONSE
LETTER IN
RELATION TO NEW DRUG APPLICATION (NDA) FOR TACLANTIS
    * FDA OFFICE OF NEW DRUGS REQUESTED CONDUCT OF A NEW PHASE 3
STUDY
IN METASTATIC BREAST CANCER PATIENTS
    * WILL REVIEW FDA'S RESPONSE AND DECIDE ON APPROPRIATE NEXT
STEPS
SOON

Source text for Eikon:  ID:nBSE82MdmY 
Further company coverage:  SPRC.NS 

 ((bangalore.newsroom@thomsonreuters.com;))